ArcticZymes Technologies — M&A Activity 2023

May 3, 2023

ArcticZymes Technologies and Genovis enter into a collaboration agreement to accelerate growth in China.

ArcticZymes Technologies and Genovis enter into a collaboration agreement to accelerate growth in China.

Tromsø, May 3[rd]  2023 - ArcticZymes Technologies ASA (OSE: AZT) and Genovis

are excited to announce a collaboration to speed up penetration and growth in

the Chinese market.

The collaboration will create several synergies that will allow both companies

to tap into the projected growth potential in China for their respective market

segments. The focus of the collaboration will be on sharing Business Development

resources and engaging in joint Marketing activities.  The joint effort will

allow both companies to have a direct presence in the Chinese market with local

resources.

According to Dirk Hahneiser, VP of Business Development & Marketing,

ArcticZymes: "Sharing our resources will not only leverage economies of scale,

increased profitability, and long-term value creation for shareholders, but also

frees up resources to focus even more on our customers and their needs."

Rikke Rytter, VP Sales & Marketing at Genovis, says, "We're excited about the

collaboration because joining forces enables both Nordic enzyme companies to

leverage synergies, amplify impact, mitigate risk, and expand our respective

presence in this fast-growing market."

For more information, please contact:

ArcticZymes Technologies ASA

CFO, Børge Sørvoll Tel: +47 952 90187

ir@arcticzymes.com

Genovis AB

CEO, Fredrik Olsson Tel: +46 (0)70 276 46 56

fredrik.olsson@genovis.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the

development, manufacturing and commercialization of novel recombinant enzymes

for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

The company is listed on the Oslo Stock Exchange since 2005 as ArcticZymes

Technologies under the [AZT] ticker. Its headquarters are based in Tromsø,

Norway, at the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large

portfolio of patents.

For more information, please visit the website: www.arcticzymes.com.

About Genovis AB

Genovis' business concept is to apply its knowledge and imagination to design

and provide innovative tools for the development of the drugs of the future.

Today Genovis sells several enzyme products known as SmartEnzymesT all over the

world in innovative product formats that facilitate development and quality

control of biological drugs.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc.

(US). Genovis shares are listed on Nasdaq First North Growth Market and Erik

Penser Bank is the Company's Certified Adviser, certifiedadviser@penser.se, tel:

+46 (0)8-463 83 00.